Translating Guidelines and Clinical Trial Data to and ... - Amazon S3
Translating Guidelines and Clinical Trial Data to and ... - Amazon S3
Translating Guidelines and Clinical Trial Data to and ... - Amazon S3
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MRC R3:Mi<strong>to</strong>xantrone vs IdarubicinreeProportionProgression-Fr1.000.750.500.25Number at Risk:Mi<strong>to</strong>xantrone 103Idarubicin 109Mi<strong>to</strong>xantroneIdarubicin64.6 (54.2-73.2)35.9 (25.9-45.9)Log-rank P=.000400 12 24 36 48 60Months from R<strong>and</strong>omization7666543640202113105vingProportion Survi1.000.750.500.250Log-rank P=.004Mi<strong>to</strong>xantroneIdarubicin69.0 (58.5-77.3)45.2 (34.5-55.3)0 12 24 36 48 60Months from R<strong>and</strong>omization10310982745846No difference in reinduction rates or MRD43272316106Parker C, et al. Lancet. 2010;376(9757):2009-2017.Clofarabine in Pediatric Patients withRefrac<strong>to</strong>ry or Relapsed ALL(%)Patient Survival100CR + CRp (n=12)90CR + CRp + PR (n=18)80All patients (n=61)70CensoredAll patients (CR + CRp)60(CR + CRp + PR)504030201000 10 20 30 40 50 60 7080 90100Survival (weeks)• An open label, multicenter study• Pediatric patients with refrac<strong>to</strong>ry or relapsed ALL received clofarabine52 mg/m 2 IV daily for 5 days, every 2-6 weeks for up <strong>to</strong> 12 cyclesCRp = CR with incomplete platelet recovery; PR = partial response.Jeha S, et al. J Clin Oncol. 2006;24(12):1917-1923.
Change language